Physician profile
Tina B Verder
NPI 1285653683
$2,157.12
in general payments reported to CMS, 2019-2025
10 companies · $800 in 2025
The $800 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $50.80 · 2021: $12.02 · 2022: $41.63 · 2024: $1,122 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,800 · Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,800.00 |
| Food and Beverage | $121.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,800.00 | 2024-2025 | |
| Organon LLC | $121.95 | 2024 | |
| Abbvie INC. | $76.14 | 2019-2020 | |
| Therapeuticsmd, INC. | $40.04 | 2019 | |
| Aspira Women'S Health INC | $30.78 | 2020 | |
| Intuitive Surgical, INC. | $29.33 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.99 | 2019 | |
| Lupin INC. | $13.57 | 2019 | |
| Channel Medsystems, INC. | $12.30 | 2022 | |
| Hologic Sales and Service, LLC | $12.02 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Verder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.